Insulet falls as Omnipod 5 Pod medical device correction spotlights manufacturing issue

Insulet Corporation (PODD) is down 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to Insulet’s newly posted voluntary Medical Device Correction involving specific U.S. lots of Omnipod 5 Pods, which raises near-term concerns about product quality, patient safety risk, and potential costs for replacements and support. Even if the impacted volume is small, safety-related communications can pressure sentiment quickly for medical device makers.

Details:

Insulet posted an “URGENT” Medical Device Correction dated March 12, 2026 for certain lots of Omnipod 5 Pods distributed in the U.S., after identifying a manufacturing issue through product monitoring.

The company described a potential small tear in internal insulin-delivery tubing that could cause insulin to leak inside the Pod, creating a risk of under-delivery and high blood glucose, with severe cases potentially leading to diabetic ketoacidosis (DKA).

Insulet disclosed 18 reports of serious adverse events tied to high blood glucose, including hospitalization and DKA, and stated no deaths were reported.

Insulet said the affected Pods represent about 1.5% of annual Omnipod 5 Pod production globally, manufacturing and quality controls were updated, and it expects sufficient supply to replace impacted Pods without disrupting availability.

Sources:

Omnipod, FDA, Insulet Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$PODD Insider Trading Activity

$PODD insiders have traded $PODD stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:

ASHLEY MCEVOY (President and CEO) purchased 4,300 shares for an estimated $1,029,205
WAYNE A.I. FREDERICK sold 1,851 shares for an estimated $542,509
MICHAEL R MINOGUE purchased 2,030 shares for an estimated $499,846
TIMOTHY C. STONESIFER purchased 962 shares for an estimated $299,884

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$PODD Hedge Fund Activity

We have seen 417 institutional investors add shares of $PODD stock to their portfolio, and 425 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,299,597 shares (-74.0%) from their portfolio in Q4 2025, for an estimated $653,637,451
FMR LLC removed 1,244,468 shares (-16.4%) from their portfolio in Q4 2025, for an estimated $353,727,584
MACQUARIE GROUP LTD removed 474,325 shares (-98.7%) from their portfolio in Q4 2025, for an estimated $134,822,138
VOYA INVESTMENT MANAGEMENT LLC added 337,421 shares (+531.8%) to their portfolio in Q4 2025, for an estimated $95,908,545
RTW INVESTMENTS, LP added 324,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $92,264,304
AQR CAPITAL MANAGEMENT LLC added 283,643 shares (+161.6%) to their portfolio in Q4 2025, for an estimated $80,622,686
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 258,775 shares (+inf%) to their portfolio in Q4 2025, for an estimated $73,554,206

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$PODD Analyst Ratings

Wall Street analysts have issued reports on $PODD in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Underweight" rating on 01/12/2026
Truist Securities issued a "Buy" rating on 12/18/2025
Canaccord Genuity issued a "Buy" rating on 11/24/2025
RBC Capital issued a "Outperform" rating on 11/21/2025
BTIG issued a "Buy" rating on 11/21/2025
UBS issued a "Buy" rating on 11/19/2025
Wells Fargo issued a "Overweight" rating on 11/07/2025

To track analyst ratings and price targets for $PODD, check out Quiver Quantitative's $PODD forecast page.

$PODD Price Targets

Multiple analysts have issued price targets for $PODD recently. We have seen 18 analysts offer price targets for $PODD in the last 6 months, with a median target of $357.5.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $338.0 on 03/11/2026
Robbie Marcus from JP Morgan set a target price of $340.0 on 02/19/2026
Mike Kratky from Leerink Partners set a target price of $360.0 on 02/19/2026
Richard Newitter from Truist Securities set a target price of $360.0 on 02/19/2026
David Roman from Goldman Sachs set a target price of $326.0 on 02/19/2026
Lee Hambright from Bernstein set a target price of $330.0 on 02/19/2026
Suraj Kalia from Oppenheimer set a target price of $300.0 on 02/19/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.